A Christopher Boyd
Overview
Explore the profile of A Christopher Boyd including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
887
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Davies J, Polineni D, Boyd A, Donaldson S, Gill D, Griesenbach U, et al.
Am J Respir Crit Care Med
. 2024 Sep;
210(12):1398-1408.
PMID: 39236265
Cystic fibrosis (CF) is a genetic disease caused by mutations in the (cystic fibrosis transmembrane conductance regulator) gene. Although CF is a multiorgan disease, the leading causes of morbidity and...
2.
Moiseenko A, Sinadinos A, Sergijenko A, Pineault K, Saleh A, Nekola K, et al.
Eur Respir J
. 2024 Aug;
65(1).
PMID: 39174284
Rationale And Objective: Cystic fibrosis (CF) is caused by mutations in the CF transmembrane conductance regulator (CFTR) gene. CFTR modulators offer significant improvements, but ∼10% of patients remain nonresponsive or...
3.
Taylor-Cousar J, Boyd A, Alton E, Polineni D
Curr Opin Pulm Med
. 2023 Sep;
29(6):615-620.
PMID: 37700667
Purpose Of Review: Advances in cystic fibrosis (CF) therapies over the past decade pivotally changed the morbidity and mortality of CF with the advent of cystic fibrosis transmembrane conductance regulator...
4.
McLachlan G, Alton E, Boyd A, Clarke N, Davies J, Gill D, et al.
Hum Gene Ther
. 2022 Sep;
33(17-18):893-912.
PMID: 36074947
The prospect of gene therapy for inherited and acquired respiratory disease has energized the research community since the 1980s, with cystic fibrosis, as a monogenic disorder, driving early efforts to...
5.
Alton E, Boyd A, Davies J, Gill D, Griesenbach U, Harman T, et al.
Hum Gene Ther
. 2020 Aug;
31(17-18):911-916.
PMID: 32746737
No abstract available.
6.
Boyd A, Guo S, Huang L, Kerem B, Oren Y, Walker A, et al.
J Cyst Fibros
. 2020 Jan;
19 Suppl 1:S54-S59.
PMID: 31948871
Gene therapy offers great promise for cystic fibrosis which has never been quite fulfilled due to the challenges of delivering sufficient amounts of the CFTR gene and expression persistence for...
7.
Alton E, Beekman J, Boyd A, Brand J, Carlon M, Connolly M, et al.
Thorax
. 2016 Nov;
72(2):137-147.
PMID: 27852956
We have recently shown that non-viral gene therapy can stabilise the decline of lung function in patients with cystic fibrosis (CF). However, the effect was modest, and more potent gene...
8.
Alton E, Boyd A, Davies J, Gill D, Griesenbach U, Harrison P, et al.
Pediatr Pulmonol
. 2016 Sep;
51(S44):S5-S17.
PMID: 27662105
Since identification of the CFTR gene over 25 years ago, gene therapy for cystic fibrosis (CF) has been actively developed. More recently gene therapy has been joined by other forms...
9.
Alton E, Boyd A, Porteous D, Davies G, Davies J, Griesenbach U, et al.
Am J Respir Crit Care Med
. 2015 Dec;
192(11):1389-92.
PMID: 26623687
No abstract available.
10.
Alton E, Armstrong D, Ashby D, Bayfield K, Bilton D, Bloomfield E, et al.
Lancet Respir Med
. 2015 Jul;
3(9):684-691.
PMID: 26149841
Background: Lung delivery of plasmid DNA encoding the CFTR gene complexed with a cationic liposome is a potential treatment option for patients with cystic fibrosis. We aimed to assess the...